Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Benzinga · 3d ago
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.